Bayer CropScience Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: March 6, 2026, 3:40 am

Market Cap	20,286 Cr.
Current Price	4,514
Intrinsic Value	₹3,489.24
High / Low	6,540/4,273
Stock P/E	30.3
Book Value	695
Dividend Yield	2.77 %
ROCE	24.8 %
ROE	20.0 %
Face Value	10.0
PEG Ratio	39.51

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Bayer CropScience Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Bayer CropScience Ltd	20,286 Cr.	4,514	6,540/4,273	30.3	695	2.77 %	24.8 %	20.0 %	10.0
Sumitomo Chemical India Ltd	19,831 Cr.	397	665/367	36.6	64.0	0.30 %	25.1 %	18.8 %	10.0
Atul Ltd	19,411 Cr.	6,561	7,793/4,752	32.7	2,010	0.38 %	12.8 %	9.10 %	10.0
Sharda Cropchem Ltd	9,628 Cr.	1,067	1,298/440	17.0	297	0.84 %	16.5 %	12.6 %	10.0
Rallis India Ltd	5,004 Cr.	257	386/197	27.2	106	0.97 %	10.1 %	6.65 %	1.00
Industry Average	9,974.35 Cr	1,046.17		26.51	369.00	0.51%	15.21%	19.87%	6.67

All Competitor Stocks of Bayer CropScience Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	1,038	982	1,740	1,617	955	792	1,631	1,738	1,057	1,046	1,915	1,553	1,106
Expenses	952	777	1,315	1,312	827	695	1,317	1,554	1,037	876	1,566	1,348	989
Operating Profit	85	206	425	305	128	97	314	184	20	171	348	205	117
OPM %	8%	21%	24%	19%	13%	12%	19%	11%	2%	16%	18%	13%	11%
Other Income	116	24	21	16	15	29	27	24	32	37	19	14	16
Interest	3	7	8	4	3	5	4	3	4	6	5	4	5
Depreciation	14	27	31	12	15	16	22	14	15	34	27	14	15
Profit before tax	184	195	406	306	124	105	316	190	34	168	335	200	113
Tax %	27%	19%	19%	27%	25%	9%	20%	28%	-2%	15%	17%	24%	15%
Net Profit	134	158	328	223	93	96	254	136	34	143	279	153	96
EPS in Rs	29.93	35.27	73.09	49.60	20.72	21.36	56.56	30.33	7.61	31.89	62.01	33.98	21.29

Last Updated: March 3, 2026, 11:54 am

Below is a detailed analysis of the quarterly data for Bayer CropScience Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

For Sales, as of Dec 2025, the value is 1,106.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,553.00 Cr. (Sep 2025) to 1,106.00 Cr., marking a decrease of 447.00 Cr..
For Expenses, as of Dec 2025, the value is 989.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,348.00 Cr. (Sep 2025) to 989.00 Cr., marking a decrease of 359.00 Cr..
For Operating Profit, as of Dec 2025, the value is 117.00 Cr.. The value appears to be declining and may need further review. It has decreased from 205.00 Cr. (Sep 2025) to 117.00 Cr., marking a decrease of 88.00 Cr..
For OPM %, as of Dec 2025, the value is 11.00%. The value appears to be declining and may need further review. It has decreased from 13.00% (Sep 2025) to 11.00%, marking a decrease of 2.00%.
For Other Income, as of Dec 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Sep 2025) to 16.00 Cr., marking an increase of 2.00 Cr..
For Interest, as of Dec 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.00 Cr. (Sep 2025) to 5.00 Cr., marking an increase of 1.00 Cr..
For Depreciation, as of Dec 2025, the value is 15.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.00 Cr. (Sep 2025) to 15.00 Cr., marking an increase of 1.00 Cr..
For Profit before tax, as of Dec 2025, the value is 113.00 Cr.. The value appears to be declining and may need further review. It has decreased from 200.00 Cr. (Sep 2025) to 113.00 Cr., marking a decrease of 87.00 Cr..
For Tax %, as of Dec 2025, the value is 15.00%. The value appears to be improving (decreasing) as expected. It has decreased from 24.00% (Sep 2025) to 15.00%, marking a decrease of 9.00%.
For Net Profit, as of Dec 2025, the value is 96.00 Cr.. The value appears to be declining and may need further review. It has decreased from 153.00 Cr. (Sep 2025) to 96.00 Cr., marking a decrease of 57.00 Cr..
For EPS in Rs, as of Dec 2025, the value is 21.29. The value appears to be declining and may need further review. It has decreased from 33.98 (Sep 2025) to 21.29, marking a decrease of 12.69.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 12:40 am

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	3,188	3,660	2,769	2,803	2,710	3,167	3,609	4,261	4,734	5,140	5,106	5,473	5,621
Expenses	2,768	3,144	2,334	2,389	2,300	2,684	2,883	3,450	3,923	4,216	4,147	4,783	4,779
Operating Profit	419	516	435	414	410	483	726	812	812	924	959	691	842
OPM %	13%	14%	16%	15%	15%	15%	20%	19%	17%	18%	19%	13%	15%
Other Income	91	88	82	70	39	51	-64	69	112	168	76	118	86
Interest	5	5	10	7	11	10	14	13	13	22	20	17	20
Depreciation	65	25	25	29	33	44	65	74	64	80	74	85	91
Profit before tax	441	574	482	448	404	480	583	794	847	990	941	707	816
Tax %	34%	33%	35%	35%	26%	30%	19%	38%	24%	23%	21%	20%
Net Profit	290	383	315	291	300	337	474	493	645	758	740	568	670
EPS in Rs	79.06	104.59	89.13	82.31	87.41	98.18	105.58	109.72	143.58	168.71	164.77	126.38	149.17
Dividend Payout %	7%	20%	19%	21%	21%	18%	24%	105%	104%	77%	85%	99%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	32.07%	-17.75%	-7.62%	3.09%	12.33%	40.65%	4.01%	30.83%	17.52%	-2.37%	-23.24%
Change in YoY Net Profit Growth (%)	0.00%	-49.82%	10.14%	10.71%	9.24%	28.32%	-36.64%	26.82%	-13.31%	-19.89%	-20.87%

Bayer CropScience Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	4%
5 Years:	9%
3 Years:	5%
TTM:	15%

Compounded Profit Growth
10 Years:	4%
5 Years:	0%
3 Years:	-2%
TTM:	-11%

Stock Price CAGR
10 Years:	3%
5 Years:	-3%
3 Years:	-1%
1 Year:	-21%

Return on Equity
10 Years:	21%
5 Years:	23%
3 Years:	24%
Last Year:	20%

Last Updated: September 5, 2025, 2:36 pm

Balance Sheet

Last Updated: December 4, 2025, 2:30 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	37	37	35	35	34	34	45	45	45	45	45	45	45
Reserves	1,706	1,996	1,804	2,021	1,744	2,205	2,528	2,505	2,479	2,667	2,804	2,806	3,079
Borrowings	0	0	0	0	0	0	2	26	86	74	47	105	102
Other Liabilities	645	740	597	769	756	1,310	1,262	1,663	1,742	1,893	1,701	2,290	1,966
Total Liabilities	2,387	2,773	2,437	2,825	2,535	3,549	3,836	4,239	4,353	4,679	4,597	5,246	5,191
Fixed Assets	228	322	290	342	334	440	468	425	468	462	414	470	585
CWIP	217	1	17	24	36	47	56	76	98	109	119	119	9
Investments	4	29	68	50	0	0	41	52	38	41	54	35	41
Other Assets	1,939	2,422	2,062	2,410	2,164	3,062	3,270	3,686	3,749	4,066	4,010	4,622	4,557
Total Assets	2,387	2,773	2,437	2,825	2,535	3,549	3,836	4,239	4,353	4,679	4,597	5,246	5,191

Below is a detailed analysis of the balance sheet data for Bayer CropScience Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

For Equity Capital, as of Sep 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 45.00 Cr..
For Reserves, as of Sep 2025, the value is 3,079.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,806.00 Cr. (Mar 2025) to 3,079.00 Cr., marking an increase of 273.00 Cr..
For Borrowings, as of Sep 2025, the value is 102.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 105.00 Cr. (Mar 2025) to 102.00 Cr., marking a decrease of 3.00 Cr..
For Other Liabilities, as of Sep 2025, the value is 1,966.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,290.00 Cr. (Mar 2025) to 1,966.00 Cr., marking a decrease of 324.00 Cr..
For Total Liabilities, as of Sep 2025, the value is 5,191.00 Cr.. The value appears to be improving (decreasing). It has decreased from 5,246.00 Cr. (Mar 2025) to 5,191.00 Cr., marking a decrease of 55.00 Cr..
For Fixed Assets, as of Sep 2025, the value is 585.00 Cr.. The value appears strong and on an upward trend. It has increased from 470.00 Cr. (Mar 2025) to 585.00 Cr., marking an increase of 115.00 Cr..
For CWIP, as of Sep 2025, the value is 9.00 Cr.. The value appears to be declining and may need further review. It has decreased from 119.00 Cr. (Mar 2025) to 9.00 Cr., marking a decrease of 110.00 Cr..
For Investments, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 35.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 6.00 Cr..
For Other Assets, as of Sep 2025, the value is 4,557.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,622.00 Cr. (Mar 2025) to 4,557.00 Cr., marking a decrease of 65.00 Cr..
For Total Assets, as of Sep 2025, the value is 5,191.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,246.00 Cr. (Mar 2025) to 5,191.00 Cr., marking a decrease of 55.00 Cr..

Notably, the Reserves (3,079.00 Cr.) exceed the Borrowings (102.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	282	200	206	157	121	433	666	687	216	609	952	262
Cash from Investing Activity +	-290	485	16	-8	38	-113	-29	7	64	83	0	86
Cash from Financing Activity +	-480	-42	-590	-73	-581	-158	-148	-556	-703	-613	-656	-619
Net Cash Flow	-488	644	-367	76	-421	162	489	138	-424	79	296	-272

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	419.00	516.00	435.00	414.00	410.00	483.00	724.00	786.00	726.00	850.00	912.00	586.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	47	57	53	72	89	81	73	65	77	69	69	63
Inventory Days	98	85	169	178	175	294	206	226	235	268	222	319
Days Payable	51	40	52	67	67	164	101	142	127	129	87	148
Cash Conversion Cycle	94	102	171	184	197	211	177	149	185	208	204	234
Working Capital Days	88	53	92	104	134	116	77	61	84	86	78	88
ROCE %	24%	31%	25%	23%	22%	25%	30%	31%	31%	34%	34%	25%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	71.44%	71.44%	71.44%	71.44%	71.44%	71.44%	71.44%	71.44%	71.44%	71.44%	71.44%	71.44%
FIIs	3.18%	3.18%	3.30%	3.53%	3.62%	3.63%	3.30%	3.42%	3.49%	3.64%	3.80%	3.84%
DIIs	12.74%	13.06%	13.23%	12.70%	12.80%	12.47%	12.08%	11.69%	11.56%	11.38%	11.22%	11.47%
Public	12.64%	12.32%	12.05%	12.33%	12.15%	12.47%	13.18%	13.45%	13.53%	13.55%	13.56%	13.27%
No. of Shareholders	57,253	48,404	45,329	46,907	45,852	46,201	51,289	54,289	54,216	55,753	58,109	58,571

Shareholding Pattern Chart

No. of Shareholders

Bayer CropScience Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Quant Small Cap Fund	1,037,211	1.69	463.24	986,394	2025-12-15 03:03:08	5.15%
Nippon India Small Cap Fund	560,144	0.38	250.17	559,898	2026-02-23 02:51:03	0.04%
Aditya Birla Sun Life Large Cap Fund	349,249	0.51	155.98	336,808	2026-01-26 05:24:40	3.69%
Nippon India Growth Mid Cap Fund	303,512	0.32	135.55	N/A	N/A	N/A
Aditya Birla Sun Life MNC Fund	230,758	3.01	103.06	N/A	N/A	N/A
DSP Small Cap Fund	205,460	0.57	91.76	180,663	2026-02-23 02:51:03	13.73%
Bandhan ELSS Tax Saver Fund	177,500	1.12	79.28	175,000	2026-02-23 02:51:03	1.43%
Bandhan Value Fund	160,000	0.71	71.46	155,000	2026-02-23 02:51:03	3.23%
Tata India Pharma & HealthCare Fund	92,824	3.34	41.46	N/A	N/A	N/A
DSP Multicap Fund	88,177	1.52	39.38	N/A	N/A	N/A

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	126.38	164.77	168.71	143.58	109.72
Diluted EPS (Rs.)	126.38	164.77	168.71	143.58	109.72
Cash EPS (Rs.)	145.41	181.40	186.57	158.08	126.19
Book Value[Excl.RevalReserv]/Share (Rs.)	634.83	634.61	604.03	562.20	568.00
Book Value[Incl.RevalReserv]/Share (Rs.)	634.83	634.61	604.03	562.20	568.00
Dividend / Share (Rs.)	125.00	140.00	130.00	150.00	115.00
Revenue From Operations / Share (Rs.)	1219.02	1136.57	1144.70	1054.43	949.06
PBDIT / Share (Rs.)	180.24	230.51	220.07	192.81	194.99
PBIT / Share (Rs.)	161.34	214.03	202.36	178.44	178.62
PBT / Share (Rs.)	157.55	209.66	220.51	188.60	176.95
Net Profit / Share (Rs.)	126.50	164.92	168.86	143.72	109.82
PBDIT Margin (%)	14.78	20.28	19.22	18.28	20.54
PBIT Margin (%)	13.23	18.83	17.67	16.92	18.82
PBT Margin (%)	12.92	18.44	19.26	17.88	18.64
Net Profit Margin (%)	10.37	14.51	14.75	13.63	11.57
Return on Networth / Equity (%)	19.92	25.98	27.95	25.56	19.33
Return on Capital Employeed (%)	23.96	32.03	31.31	29.74	30.05
Return On Assets (%)	10.82	16.10	16.20	14.82	11.63
Asset Turnover Ratio (%)	1.11	1.10	1.14	1.10	1.06
Current Ratio (X)	2.01	2.44	2.19	2.15	2.26
Quick Ratio (X)	0.94	1.48	1.18	1.24	1.41
Inventory Turnover Ratio (X)	2.80	1.48	1.39	1.82	2.17
Dividend Payout Ratio (NP) (%)	98.90	81.93	74.09	104.47	104.82
Dividend Payout Ratio (CP) (%)	86.04	74.48	67.06	94.98	91.22
Earning Retention Ratio (%)	1.10	18.07	25.91	-4.47	-4.82
Cash Earning Retention Ratio (%)	13.96	25.52	32.94	5.02	8.78
Interest Coverage Ratio (X)	47.61	52.81	44.31	67.11	69.48
Interest Coverage Ratio (Post Tax) (X)	34.41	38.78	30.35	46.49	39.73
Enterprise Value (Cr.)	21230.10	22377.29	17307.30	21584.03	22612.20
EV / Net Operating Revenue (X)	3.88	4.38	3.37	4.56	5.31
EV / EBITDA (X)	26.23	21.62	17.52	24.93	25.83
MarketCap / Net Operating Revenue (X)	4.04	4.61	3.54	4.73	5.59
Retention Ratios (%)	1.09	18.06	25.90	-4.47	-4.82
Price / BV (X)	7.76	8.26	6.70	8.86	9.34
Price / Net Operating Revenue (X)	4.04	4.61	3.54	4.73	5.59
EarningsYield	0.02	0.03	0.04	0.02	0.02

After reviewing the key financial ratios for Bayer CropScience Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is 126.38. This value is within the healthy range. It has decreased from 164.77 (Mar 24) to 126.38, marking a decrease of 38.39.
For Diluted EPS (Rs.), as of Mar 25, the value is 126.38. This value is within the healthy range. It has decreased from 164.77 (Mar 24) to 126.38, marking a decrease of 38.39.
For Cash EPS (Rs.), as of Mar 25, the value is 145.41. This value is within the healthy range. It has decreased from 181.40 (Mar 24) to 145.41, marking a decrease of 35.99.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 634.83. It has increased from 634.61 (Mar 24) to 634.83, marking an increase of 0.22.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 634.83. It has increased from 634.61 (Mar 24) to 634.83, marking an increase of 0.22.
For Dividend / Share (Rs.), as of Mar 25, the value is 125.00. This value exceeds the healthy maximum of 3. It has decreased from 140.00 (Mar 24) to 125.00, marking a decrease of 15.00.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,219.02. It has increased from 1,136.57 (Mar 24) to 1,219.02, marking an increase of 82.45.
For PBDIT / Share (Rs.), as of Mar 25, the value is 180.24. This value is within the healthy range. It has decreased from 230.51 (Mar 24) to 180.24, marking a decrease of 50.27.
For PBIT / Share (Rs.), as of Mar 25, the value is 161.34. This value is within the healthy range. It has decreased from 214.03 (Mar 24) to 161.34, marking a decrease of 52.69.
For PBT / Share (Rs.), as of Mar 25, the value is 157.55. This value is within the healthy range. It has decreased from 209.66 (Mar 24) to 157.55, marking a decrease of 52.11.
For Net Profit / Share (Rs.), as of Mar 25, the value is 126.50. This value is within the healthy range. It has decreased from 164.92 (Mar 24) to 126.50, marking a decrease of 38.42.
For PBDIT Margin (%), as of Mar 25, the value is 14.78. This value is within the healthy range. It has decreased from 20.28 (Mar 24) to 14.78, marking a decrease of 5.50.
For PBIT Margin (%), as of Mar 25, the value is 13.23. This value is within the healthy range. It has decreased from 18.83 (Mar 24) to 13.23, marking a decrease of 5.60.
For PBT Margin (%), as of Mar 25, the value is 12.92. This value is within the healthy range. It has decreased from 18.44 (Mar 24) to 12.92, marking a decrease of 5.52.
For Net Profit Margin (%), as of Mar 25, the value is 10.37. This value exceeds the healthy maximum of 10. It has decreased from 14.51 (Mar 24) to 10.37, marking a decrease of 4.14.
For Return on Networth / Equity (%), as of Mar 25, the value is 19.92. This value is within the healthy range. It has decreased from 25.98 (Mar 24) to 19.92, marking a decrease of 6.06.
For Return on Capital Employeed (%), as of Mar 25, the value is 23.96. This value is within the healthy range. It has decreased from 32.03 (Mar 24) to 23.96, marking a decrease of 8.07.
For Return On Assets (%), as of Mar 25, the value is 10.82. This value is within the healthy range. It has decreased from 16.10 (Mar 24) to 10.82, marking a decrease of 5.28.
For Asset Turnover Ratio (%), as of Mar 25, the value is 1.11. It has increased from 1.10 (Mar 24) to 1.11, marking an increase of 0.01.
For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has decreased from 2.44 (Mar 24) to 2.01, marking a decrease of 0.43.
For Quick Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has decreased from 1.48 (Mar 24) to 0.94, marking a decrease of 0.54.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.80. This value is below the healthy minimum of 4. It has increased from 1.48 (Mar 24) to 2.80, marking an increase of 1.32.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 98.90. This value exceeds the healthy maximum of 50. It has increased from 81.93 (Mar 24) to 98.90, marking an increase of 16.97.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 86.04. This value exceeds the healthy maximum of 50. It has increased from 74.48 (Mar 24) to 86.04, marking an increase of 11.56.
For Earning Retention Ratio (%), as of Mar 25, the value is 1.10. This value is below the healthy minimum of 40. It has decreased from 18.07 (Mar 24) to 1.10, marking a decrease of 16.97.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 13.96. This value is below the healthy minimum of 40. It has decreased from 25.52 (Mar 24) to 13.96, marking a decrease of 11.56.
For Interest Coverage Ratio (X), as of Mar 25, the value is 47.61. This value is within the healthy range. It has decreased from 52.81 (Mar 24) to 47.61, marking a decrease of 5.20.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 34.41. This value is within the healthy range. It has decreased from 38.78 (Mar 24) to 34.41, marking a decrease of 4.37.
For Enterprise Value (Cr.), as of Mar 25, the value is 21,230.10. It has decreased from 22,377.29 (Mar 24) to 21,230.10, marking a decrease of 1,147.19.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has decreased from 4.38 (Mar 24) to 3.88, marking a decrease of 0.50.
For EV / EBITDA (X), as of Mar 25, the value is 26.23. This value exceeds the healthy maximum of 15. It has increased from 21.62 (Mar 24) to 26.23, marking an increase of 4.61.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 4.61 (Mar 24) to 4.04, marking a decrease of 0.57.
For Retention Ratios (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 30. It has decreased from 18.06 (Mar 24) to 1.09, marking a decrease of 16.97.
For Price / BV (X), as of Mar 25, the value is 7.76. This value exceeds the healthy maximum of 3. It has decreased from 8.26 (Mar 24) to 7.76, marking a decrease of 0.50.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 4.61 (Mar 24) to 4.04, marking a decrease of 0.57.
For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Bayer CropScience Ltd as of March 6, 2026 is: ₹3,462.69

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 6, 2026, Bayer CropScience Ltd is Overvalued by 23.29% compared to the current share price ₹4,514.00

Intrinsic Value of Bayer CropScience Ltd as of March 6, 2026 is: ₹3,489.24

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 6, 2026, Bayer CropScience Ltd is Overvalued by 22.70% compared to the current share price ₹4,514.00

Last 5 Year EPS CAGR: 0.77%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 27.92%, which is a positive sign. The company has higher reserves (2,334.15 cr) compared to borrowings (34.00 cr), indicating strong financial stability. The company has shown consistent growth in sales (3.54 cr) and profit (654.38 cr) over the years.	The stock has a high average Working Capital Days of 88.42, which may not be favorable. The stock has a high average Cash Conversion Cycle of 176.33, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bayer CropScience Ltd:
1. Net Profit Margin: 10.37%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 23.96% (Industry Average ROCE: 15.21%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 19.92% (Industry Average ROE: 19.87%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 34.41
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.94
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 30.3 (Industry average Stock P/E: 26.51)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Bayer Cropscience Ltd. is a Public Limited Listed company incorporated on 09/09/1958 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24210MH1958PLC011173 and registration number is 011173. Currently Company is involved in the business activities of Manufacture of insecticides, rodenticides, fungicides, herbicides. Company's Total Operating Revenue is Rs. 5473.40 Cr. and Equity Capital is Rs. 44.90 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Agro Chemicals/Pesticides	Bayer House, Central Avenue, Mumbai Maharashtra 400607	Contact not found

Management
Name	Position Held
Mr. Pankaj Ramanbhai Patel	Chairman & Ind.Dire (Non-Exe)
Mr. Simon Thorsten Wiebusch	Vice Chairman & Mng.Director
Mr. Vinit Rajesh Jindal	Executive Director & CFO
Dr. Thomas Hoffmann	Non Exe.Non Ind.Director
Ms. Jana Marlen Ackermann	Non Exe.Non Ind.Director
Ms. Radhika Rajan	Ind. Non-Executive Director
Mr. Sekhar Natarajan	Ind. Non-Executive Director
Mr. Sanjiv Rangrass	Ind. Non-Executive Director

FAQ

What is the intrinsic value of Bayer CropScience Ltd?

Bayer CropScience Ltd's intrinsic value (as of 06 March 2026) is ₹3489.24 which is 22.70% lower the current market price of ₹4,514.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹20,286 Cr. market cap, FY2025-2026 high/low of ₹6,540/4,273, reserves of ₹3,079 Cr, and liabilities of ₹5,191 Cr.

What is the Market Cap of Bayer CropScience Ltd?

The Market Cap of Bayer CropScience Ltd is 20,286 Cr..

What is the current Stock Price of Bayer CropScience Ltd as on 06 March 2026?

The current stock price of Bayer CropScience Ltd as on 06 March 2026 is ₹4,514.

What is the High / Low of Bayer CropScience Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Bayer CropScience Ltd stocks is ₹6,540/4,273.

What is the Stock P/E of Bayer CropScience Ltd?

The Stock P/E of Bayer CropScience Ltd is 30.3.

What is the Book Value of Bayer CropScience Ltd?

The Book Value of Bayer CropScience Ltd is 695.

What is the Dividend Yield of Bayer CropScience Ltd?

The Dividend Yield of Bayer CropScience Ltd is 2.77 %.

What is the ROCE of Bayer CropScience Ltd?

The ROCE of Bayer CropScience Ltd is 24.8 %.

What is the ROE of Bayer CropScience Ltd?

The ROE of Bayer CropScience Ltd is 20.0 %.

What is the Face Value of Bayer CropScience Ltd?

The Face Value of Bayer CropScience Ltd is 10.0.